Abstract Details
|
Martin Hardmeier, MD
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| Florian Hatz, MD | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| David Leppert, MD (University Hospital Basel) | Dr. Leppert has received personal compensation for serving as an employee of GeNeuro. Dr. Leppert has received personal compensation for serving as an employee of GeNeuro. Dr. Leppert has received personal compensation for serving as an employee of Geneuro. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Leppert has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Leppert has received personal compensation in the range of $0-$499 for serving as a Consultant for Orion. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quanterix. Dr. Leppert has stock in Novartis. |
| Ludwig Kappos, MD, FAAN (RC2NB, University Hospital Basel) | Dr. Kappos has nothing to disclose. |
| Peter Fuhr, MD, FAAN | The institution of Dr. Fuhr has received research support from Roche. |